Antinociceptive effects of mixtures of mu opioid receptor agonists and cannabinoid receptor agonists in rats: Impact of drug and fixed‐dose ratio

No abstract is available for this paper.

• Publication year

  2018

• Venue

  European Journal of Pharmacology

• Publication date

  2018-01-15

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.ejphar.2017.11.038PMID 29183835PMCID PMC5766417
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Opioid-Sparing Effect of Cannabinoids: A Systematic Review and Meta-Analysis

  2017cited by this paper
• CDC guideline for prescribing opioids for chronic pain

  2016cited by this paper
• Peripheral interactions between cannabinoid and opioid receptor agonists in a model of inflammatory mechanical hyperalgesia.

  2016cited by this paper
• Interactions between cannabinoid receptor agonists and mu opioid receptor agonists in rhesus monkeys discriminating fentanyl.

  2016cited by this paper
• Opioid and cannabinoid synergy in a mouse neuropathic pain model

  2016cited by this paper
• Effects of daily delta-9-tetrahydrocannabinol treatment on heroin self-administration in rhesus monkeys

  2016cited by this paper
• Additive antinociceptive effects of mixtures of the &kgr;-opioid receptor agonist spiradoline and the cannabinoid receptor agonist CP55940 in rats

  2016cited by this paper
• CDC Guideline for Prescribing Opioids for Chronic Pain--United States, 2016.

  2016cited by this paper
• Increases in Drug and Opioid Overdose Deaths--United States, 2000-2014.

  2016cited by this paper
• The prescription opioid and heroin crisis: a public health approach to an epidemic of addiction.

  2015cited by this paper
• Impact of Efficacy at the μ-Opioid Receptor on Antinociceptive Effects of Combinations of μ-Opioid Receptor Agonists and Cannabinoid Receptor Agonists

  2014cited by this paper
• Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999-2010.

  2014cited by this paper
• Interactions between μ-Opioid Receptor Agonists and Cannabinoid Receptor Agonists in Rhesus Monkeys: Antinociception, Drug Discrimination, and Drug Self-Administration

  2013cited by this paper
• RELIEVING PAIN IN AMERICA: A BLUEPRINT FOR TRANSFORMING PREVENTION, CARE, EDUCATION, AND RESEARCH

  2012cited by this paper
• Sex Differences in Cannabinoid 1 vs. Cannabinoid 2 Receptor-Selective Antagonism of Antinociception Produced by Δ9-Tetrahydrocannabinol and CP55,940 in the Rat

  2012cited by this paper
• Interactions between &Dgr;9-tetrahydrocannabinol and heroin: self-administration in rhesus monkeys

  2012cited by this paper
• Effects of Alterations in Cannabinoid Signaling, Alone and in Combination with Morphine, on Pain-Elicited and Pain-Suppressed Behavior in Mice

  2012cited by this paper
• Apparent Inverse Relationship between Cannabinoid Agonist Efficacy and Tolerance/Cross-Tolerance Produced by Δ9-Tetrahydrocannabinol Treatment in Rhesus Monkeys

  2012cited by this paper
• THC−methadone and THC−naltrexone interactions on discrimination, antinociception, and locomotion in rats

  2011cited by this paper
• Sex-dependent effects of periadolescent exposure to the cannabinoid agonist CP-55,940 on morphine self-administration behaviour and the endogenous opioid system.

  2008cited by this paper
• Interactions between Δ9-tetrahydrocannabinol and μ opioid receptor agonists in rhesus monkeys: discrimination and antinociception

  2008cited by this paper
• Synergy between delta9-tetrahydrocannabinol and morphine in the arthritic rat.

  2007cited by this paper
• Low dose combination of morphine and delta9-tetrahydrocannabinol circumvents antinociceptive tolerance and apparent desensitization of receptors.

  2007cited by this paper
• Synergy between Δ9-tetrahydrocannabinol and morphine in the arthritic rat

  2007cited by this paper
• Response to Comments on “Isobolographic Analysis for Combinations of a Full and Partial Agonist: Curved Isoboles”

  2006cited by this paper
• An Overview of Drug Combination Analysis with Isobolograms

  2006cited by this paper
• Synergistic affective analgesic interaction between delta-9-tetrahydrocannabinol and morphine.

  2006cited by this paper
• Time course of the enhancement and restoration of the analgesic efficacy of codeine and morphine by delta9-tetrahydrocannabinol.

  2006cited by this paper
• Enhancement of transdermal fentanyl and buprenorphine antinociception by transdermal delta9-tetrahydrocannabinol.

  2005cited by this paper
• Synergistic and additive interactions of the cannabinoid agonist CP55,940 with μ opioid receptor and α2‐adrenoceptor agonists in acute pain models in mice

  2005cited by this paper
• Isobolographic Analysis for Combinations of a Full and Partial Agonist: Curved Isoboles

  2004cited by this paper
• Fitting Models to Biological Data Using Linear and Nonlinear Regression: A Practical Guide to Curve Fitting

  2004cited by this paper
• Topical cannabinoid enhances topical morphine antinociception

  2003cited by this paper
• Antinociceptive Synergy between Δ9-Tetrahydrocannabinol and Opioids after Oral Administration

  2003cited by this paper
• Sex Differences in Opioid Analgesia: “From Mouse to Man”

  2003cited by this paper
• Antinociceptive, behavioural and neuroendocrine effects of CP 55,940 in young rats.

  2002cited by this paper
• Sex differences in antinociceptive and motoric effects of cannabinoids.

  2001cited by this paper
• Drug Synergism and Dose-Effect Data Analysis

  2000cited by this paper
• Sex-related differences in the antinociceptive effects of opioids: importance of rat genotype, nociceptive stimulus intensity, and efficacy at the µ opioid receptor

  2000cited by this paper
• The neurobiology of cannabinoid dependence: sex differences and potential interactions between cannabinoid and opioid systems.

  1999cited by this paper
• Enhancement of μ Opioid Antinociception by Oral Δ9-Tetrahydrocannabinol: Dose-Response Analysis and Receptor Identification

  1999cited by this paper
• Antinociceptive effects of opioids following acute and chronic administration of butorphanol: influence of stimulus intensity and relative efficacy at the mu receptor

  1999cited by this paper
• Cannabinoid Receptor Agonist Efficacy for Stimulating [35S]GTPγS Binding to Rat Cerebellar Membranes Correlates with Agonist-induced Decreases in GDP Affinity*

  1998cited by this paper
• The Enhancement of Morphine Antinociception in Mice by Δ9-Tetrahydrocannabinol

  1998cited by this paper
• In vivo apparent affinity and efficacy estimates for μ opiates in a rat tail-withdrawal assay

  1998cited by this paper
• The enhancement of morphine antinociception in mice by delta9-tetrahydrocannabinol.

  1998cited by this paper
• Investigation of brain sites mediating cannabinoid-induced antinociception in rats: evidence supporting periaqueductal gray involvement.

  1996cited by this paper
• The role of endogenous opioids in enhancing the antinociception produced by the combination of delta 9-tetrahydrocannabinol and morphine in the spinal cord.

  1996cited by this paper
• Perinatal exposure toΔ9-tetrahydrocannabinol (Δ9-THC) leads to changes in opioid-related behavioral patterns in rats

  1995cited by this paper
• Perinatal exposure to delta 9-tetrahydrocannabinol (delta 9-THC) leads to changes in opioid-related behavioral patterns in rats.

  1995cited by this paper
• Development of tolerance to the analgesic activity of mu agonists after continuous infusion of morphine, meperidine or fentanyl in rats.

  1992cited by this paper
• Antinociceptive activity of intrathecally administered cannabinoids alone, and in combination with morphine, in mice.

  1992cited by this paper
• Spinal and supraspinal components of cannabinoid-induced antinociception.

  1991cited by this paper
• Approaches to the study of drug interactions in behavioral pharmacology.

  1986cited by this paper
• A Multiple Comparison Procedure for Comparing Several Treatments with a Control

  1955cited by this paper

• Does cannabis use substitute for opioids? A preliminary exploratory survey in opioid maintenance patients

  2024cites this paper
• Cannabinoid Analgesia in Postoperative Pain Management: From Molecular Mechanisms to Clinical Reality

  2024cites this paper
• ASRA Pain Medicine consensus guidelines on the management of the perioperative patient on cannabis and cannabinoids

  2023cites this paper
• Impact of Δ9-Tetrahydrocannabinol and oxycodone co-administration on measures of antinociception, dependence, circadian activity, and reward in mice

  2023cites this paper
• Antinociceptive and adverse effects of morphine:ketamine mixtures in rats

  2023cites this paper
• Effects of Δ⁹-tetrahydrocannabinol (THC), cannabidiol (CBD), and THC/CBD mixtures on fentanyl versus food choice in rhesus monkeys.

  2023cites this paper
• Modulation of Morphine Analgesia, Antinociceptive Tolerance, and Mu-Opioid Receptor Binding by the Cannabinoid CB2 Receptor Agonist O-1966

  2022cites this paper
• The Effect of Preoperative Marijuana Use on Surgical Outcomes, Patient-Reported Outcomes, and Opioid Consumption Following Lumbar Fusion

  2022cites this paper
• Opioid-sparing effect of cannabinoids for analgesia: an updated systematic review and meta-analysis of preclinical and clinical studies

  2022cites this paper
• In response to the study “a randomized trial of medical cannabis in patients with stage for cancers to assess feasibility, dose requirements, impact on pain and opioid use, safety, and overall patient’s satisfaction” by Dr. Zylla and colleagues

  2022cites this paper
• No antinociceptive synergy between morphine and delta-9-tetrahydrocannabinol in male and female rats with persistent inflammatory pain

  2021cites this paper
• Enhancement of Opioid Antinociception by Nicotinic Ligands

  2021cites this paper
• Interactions between opioids and cannabinoids: Economic demand for opioid/cannabinoid mixtures.

  2020cites this paper
• The role of cannabinoids in the treatment of cancer.

  2020cites this paper
• Cannabinoids in the Treatment of Back Pain.

  2020cites this paper
• Endogenous Opiates and Behavior: 2018.

  2020cites this paper
• Perspectives on cannabis as a substitute for opioid analgesics.

  2019cites this paper
• Pharmacological assessment of adjuncts to enhance mu-opioid receptor agonist antinociception in male rhesus monkeys: Does one + one = three?

  2019cites this paper
• Effects of Opioid/Cannabinoid Mixtures on Impulsivity and Memory in Rhesus Monkeys

  2019cites this paper
• Cannabis-based medicines and the perioperative physician

  2019cites this paper
• Antinociceptive and Abuse Potential Effects of Cannabinoid/Opioid Combinations in a Chronic Pain Model in Rats

  2019cites this paper
• Treatment using cannabidiol in a horse with mechanical allodynia

  2019cites this paper
• Enhancement of Opioid Antinociception by Nicotine

  2019cites this paper
• Preparation of bivalent agonists for targeting the mu opioid and cannabinoid receptors.

  2019cites this paper
• Combining opioids and non-opioids for pain management: Current status.

  2019cites this paper
• Bifunctional opioid receptor ligands as novel analgesics.

  2019cites this paper
• Comparison of null models for combination drug therapy reveals Hand model as biochemically most plausible

  2018cites this paper